Shanghai Juncell Therapeutics
Clinical trials sponsored by Shanghai Juncell Therapeutics, explained in plain language.
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are genetically modified in a lab to better attack cancer. It is for adults with advanced solid tumors that have not responded to standard therapies. The main goals are to …
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated May 17, 2026 10:40 UTC
-
Lung cancer Patients' own immune cells could shrink tumors in new trial
Disease control Not yet recruitingThis phase II trial tests a treatment called GC101 TIL, which uses immune cells taken from a patient's own lung tumor. These cells are grown in a lab and then infused back into the patient to attack the cancer. The study involves 28 adults with non-small cell lung cancer who have…
Phase: PHASE2 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Immune cells from your own tumor could fight advanced cancer
Disease control Not yet recruitingThis early study tests a new treatment for adults with advanced solid tumors that have not responded to standard therapies. Doctors take immune cells from a patient's own tumor, grow them in a lab, and then give them back through an IV. The goal is to see if this approach is safe…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:01 UTC